Floatz logo

Eganelisib

Squamous Cell Cancer of the Head and Neck (Part E)

Infinity Pharmaceuticals, Inc.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

250 Active assets in the Squamous Cell Cancer of the Head and Neck (Part E) cohort.

Asset / SponsorPhaseRating
Carboplatin
Akeso
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Eganelisib is also rated in:

cancerDormant
B
Indicative ·
58 / 100
View asset →
urinary bladder carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →